Carbohydrate restriction in patients with advanced cancer: A protocol to assess safety and feasibility with an accompanying hypothesis

Eugene J. Fine; C. J. Segal-Isaacson; Richard Feinman; Joseph Sparano

doi:10.1016/S1548-5315(11)70179-6

Carbohydrate restriction in patients with advanced cancer: A protocol to assess safety and feasibility with an accompanying hypothesis

Eugene J. Fine, C. J. Segal-Isaacson, Richard Feinman, Joseph Sparano

Research output: Contribution to journal › Article › peer-review

12 Scopus citations

Abstract

Dietary carbohydrate restriction provokes systemic metabolic and cell signaling effects including down-regulation of insulin, insulin-like growth factors, fatty acid synthase, and other enzymatic and signaling targets. These effects as well as increased availability of fatty acids and ketone bodies may plausibly inhibit aggressive glycolytic cancers. We have designed a 28-day clinical trial diet of very low carbohydrate intake under nutritionist guidance to test the safety and feasibility in patients with advanced glucose-dependent solid cancers, determined by a positive baseline positron emission tomography (PET) scan using 18-fluorodeoxyglucose to demonstrate glucose avidity. Changes in a follow-up PET scan at study's end permit a surrogate measure of efficacy.

Original language	English (US)
Pages (from-to)	22-26
Number of pages	5
Journal	Community Oncology
Volume	5
Issue number	1
DOIs	https://doi.org/10.1016/S1548-5315(11)70179-6
State	Published - Jan 2008
Externally published	Yes

ASJC Scopus subject areas

Hematology
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S1548-5315(11)70179-6

Cite this

@article{08dc2f9275624bce879fbf2a1219e288,

title = "Carbohydrate restriction in patients with advanced cancer: A protocol to assess safety and feasibility with an accompanying hypothesis",

abstract = "Dietary carbohydrate restriction provokes systemic metabolic and cell signaling effects including down-regulation of insulin, insulin-like growth factors, fatty acid synthase, and other enzymatic and signaling targets. These effects as well as increased availability of fatty acids and ketone bodies may plausibly inhibit aggressive glycolytic cancers. We have designed a 28-day clinical trial diet of very low carbohydrate intake under nutritionist guidance to test the safety and feasibility in patients with advanced glucose-dependent solid cancers, determined by a positive baseline positron emission tomography (PET) scan using 18-fluorodeoxyglucose to demonstrate glucose avidity. Changes in a follow-up PET scan at study's end permit a surrogate measure of efficacy.",

author = "Fine, {Eugene J.} and Segal-Isaacson, {C. J.} and Richard Feinman and Joseph Sparano",

year = "2008",

month = jan,

doi = "10.1016/S1548-5315(11)70179-6",

language = "English (US)",

volume = "5",

pages = "22--26",

journal = "Community Oncology",

issn = "1548-5315",

publisher = "BioLink Communications",

number = "1",

}

TY - JOUR

T1 - Carbohydrate restriction in patients with advanced cancer

T2 - A protocol to assess safety and feasibility with an accompanying hypothesis

AU - Fine, Eugene J.

AU - Segal-Isaacson, C. J.

AU - Feinman, Richard

AU - Sparano, Joseph

PY - 2008/1

Y1 - 2008/1

N2 - Dietary carbohydrate restriction provokes systemic metabolic and cell signaling effects including down-regulation of insulin, insulin-like growth factors, fatty acid synthase, and other enzymatic and signaling targets. These effects as well as increased availability of fatty acids and ketone bodies may plausibly inhibit aggressive glycolytic cancers. We have designed a 28-day clinical trial diet of very low carbohydrate intake under nutritionist guidance to test the safety and feasibility in patients with advanced glucose-dependent solid cancers, determined by a positive baseline positron emission tomography (PET) scan using 18-fluorodeoxyglucose to demonstrate glucose avidity. Changes in a follow-up PET scan at study's end permit a surrogate measure of efficacy.

AB - Dietary carbohydrate restriction provokes systemic metabolic and cell signaling effects including down-regulation of insulin, insulin-like growth factors, fatty acid synthase, and other enzymatic and signaling targets. These effects as well as increased availability of fatty acids and ketone bodies may plausibly inhibit aggressive glycolytic cancers. We have designed a 28-day clinical trial diet of very low carbohydrate intake under nutritionist guidance to test the safety and feasibility in patients with advanced glucose-dependent solid cancers, determined by a positive baseline positron emission tomography (PET) scan using 18-fluorodeoxyglucose to demonstrate glucose avidity. Changes in a follow-up PET scan at study's end permit a surrogate measure of efficacy.

UR - http://www.scopus.com/inward/record.url?scp=38949193472&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38949193472&partnerID=8YFLogxK

U2 - 10.1016/S1548-5315(11)70179-6

DO - 10.1016/S1548-5315(11)70179-6

M3 - Article

AN - SCOPUS:38949193472

SN - 1548-5315

VL - 5

SP - 22

EP - 26

JO - Community Oncology

JF - Community Oncology

IS - 1

ER -

Carbohydrate restriction in patients with advanced cancer: A protocol to assess safety and feasibility with an accompanying hypothesis

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this